Last updated on February 2020

Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households

Brief description of study

Otherwise healthy index patients (IP) are randomized to either baloxavir marboxil or placebo if their influenza symptoms onset was within 48 hours of screen. Their households are enrolled within 24 hours of randomization if at least 2 household contacts (HHC) have not received influenza vaccine within 6 months of screening and if all HHC screen negative for influenza infection. The main endpoints are assessed based on multiple respiratory swabs obtained from both IP and HHC up to 9 (+/-1) days post IP randomization.

Clinical Study Identifier: NCT03969212

Find a site near you

Start Over

Mashiba Clinic

Hanno, Japan
  Connect »

Wakasa Clinic

Tokorozawa, Japan
  Connect »